A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Purpose To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO) in combination with gemcitabine; secondary objectives include the evaluation of safety, tolerability, pharmacokinetics, biomarkers of Notch signaling and preliminary anti-tumor activity. Methods Patie...

Full description

Bibliographic Details
Main Authors: Richter, Suzanne, Bedard, Philippe L., Chen, Eric Xueyu, Clarke, Blaise A., Tran, Ben, Hotte, Sebastien J., Stathis, Anastasios, Hirte, Hal W., Razak, Albiruni R. A., Reedijk, Michael, Chen, Zhuo, Cohen, Brenda, Zhang, Wen-Jiang, Wang, Lisa, Ivy, S. Percy, Moore, Malcolm J., Oza, Amit M., Siu, Lillian L., McWhirter, Elaine
Format: Online
Language:English
Published: Springer US 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869895/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869895/

Similar Items